Esculentoside A suppresses Aβ1–42-induced neuroinflammation by down-regulating MAPKs pathways in vivo

doi:10.1179/1743132815Y.0000000066

Paper

Esculentoside A suppresses Aβ1–42-induced neuroinflammation by down-regulating MAPKs pathways in vivo

Published Jun 23, 2015 · Hui Yang, Sulei Wang, Linjie Yu

Neurological Research

Q2 SJR score

29

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract Introduction: Esculentoside A (EsA) is a saponin isolated from the roots of Phytolacca esculenta. Previous studies have demonstrated that EsA exerts strong anti-inflammatory effects in peripheral immune inflammation. This study is to determine whether EsA is effective in inflammation-related neurodegenerative diseases, such as Alzheimer's disease (AD). Methods: Male C57BL/6(B6) mice were divided into three groups of six mice as follows: (1) control group; (2) AD model group (Aβ1–42-induced AD mice with saline); (3) EsA group (Aβ1–42-induced AD mice with EsA, 5 mg/kg/day, i.p. for 15 days). Behavioural testing was performed after 15 days of EsA treatment. Real time PCR and Western blot were used to assess the level of inflammation factors and mitogen-activated protein kinases (MAPKs). Immunostaining was used to determine the level of activated microglia and astrocyte. Results: The results showed that EsA attenuated memory deficits in Aβ1–42-induced AD mice. Esculentoside A decreased the pro-inflammatory factors and microglia and astrocyte activation in the hippocampi of Aβ1–42-induced AD mice. Moreover, Aβ1–42 activated phosphorylation of ERK, JNK and p38 MAPKs in the hippocampi of mice in the AD model group, while EsA significantly decreased the phosphorylation levels. Conclusion: These findings indicate that EsA provides protective effects against neuroinflammation triggered by β-amyloid.

RCT

Animal Study

Study Snapshot

Esculentoside A (EsA) protects against neuroinflammation triggered by -amyloid in Alzheimer's disease mice by down-regulating MAPKs pathways.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Esculentoside A suppresses Aβ1–42-induced neuroinflammation by down-regulating MAPKs pathways in vivo

Sign up to use Study Snapshot

References

TL-2 attenuates β-amyloid induced neuronal apoptosis through the AKT/GSK-3β/β-catenin pathway.

TL-2, a potential Alzheimer's disease treatment, inhibits neuronal apoptosis and memory deficits by activating the AKT/GSK-3/-catenin pathway.

Oridonin Attenuates Aβ1–42-Induced Neuroinflammation and Inhibits NF-κB Pathway

Oridonin, a compound from Rabdosia rubescens, inhibits neuroinflammation and memory deficits induced by A1-42, suggesting it may be a promising candidate for Alzheimer's disease treatment.

SYNTHESIS AND BIOLOGICAL ACTIVITIES OF THE Aβ40 DIMER WITH TOXIC CONFORMATION

Pathological tau protein disrupts ribosomal function, impairing protein production, resulting in memory impairment in human brains.

Hydroxy-safflor yellow A attenuates Aβ1-42-induced inflammation by modulating the JAK2/STAT3/NF-κB pathway

Hydroxy-safflor yellow A (HSYA) protects against Alzheimer's disease by inhibiting inflammation, potentially through the JAK2/STAT3/NF- B pathway.

Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo

CysLT1R is involved in A1-42-induced neurotoxicity, and blocking CysLT1R with an antagonist like pranlukast could be a promising treatment for Alzheimer's disease.

Neuroinflammation: The role and consequences

Neuroinflammation accelerates long-term neurodegenerative diseases, including dementia, and combining preventative and therapeutic approaches may be effective in reducing its impact.

c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo

Inhibiting JNK with D-JNKI1 could prevent synaptic dysfunction and spine degeneration in Alzheimer's disease.

Protective effect of esculentoside A on lipopolysaccharide-induced acute lung injury in mice.

Esculentoside A (EsA) from Phytolacca esculenta shows potential as a preventive agent for acute lung injury by reducing inflammation and promoting healing through inhibition of nuclear factor kappa B and mitogen activated protein kinase signaling pathways.

α-Iso-cubebene exerts neuroprotective effects in amyloid beta stimulated microglia activation

-iso-cubebene, a component of Schisandra chinensis, provides neuroprotection against amyloid beta-induced neuroinflammation by inhibiting NF-B and MAPK signaling pathways.

Citations

Comparative proteomic analysis of cerebral cortex revealed neuroprotective mechanism of esculentoside A on Alzheimer's disease.

Esculentoside A (EsA) shows neuroprotective effects in Alzheimer's disease mouse models, restoring protein expression linked to metabolism, synapses, apoptosis, learning, and memory, suggesting potential as a therapeutic agent.

Esculentoside A ameliorates DNCB‐induced atopic dermatitis by suppressing the ROS‐NLRP3 axis via activating the Nrf2 pathway

Esculentoside A improves atopic dermatitis symptoms, inflammation, and oxidative stress in mice by activating the Nrf2 pathway and inactivating NLRP3 inflammasome.

Knockdown of SEMA7A alleviates MPP+‐induced apoptosis and inflammation in BV2 microglia via PPAR‐γ activation and MAPK inactivation

SEMA7A may play a role in neurodegenerative diseases, but its role in Parkinson's disease remains unclear.

The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer's disease.

Esculentoside A reduces cognitive decline in Alzheimer's disease mice by targeting tau hyperphosphorylation and autophagic clearance in an AMPK-dependent manner.

Mitigating Effect of Estrogen in Alzheimer’s Disease-Mimicking Cerebral Organoid

Estrogen shows potential as a treatment agent for Alzheimer's disease, alleviating its effects in a stem cell-based in vitro system.